FDA Drug Approval and Action Monitor: Regulatory Catalyst Data

See the FDA decisions that move biotech and pharma stocks. Provide one or more company names and get their FDA regulatory events from Drugs@FDA: new drug approvals, new indications, priority reviews and other actions - classified, scored by potential market impact, and ranked most-recent-first. A curated regulatory-catalyst dataset, not a raw application dump.

Run it on Apify

What it does

Event classification: new approval (original NDA/BLA), new indication / efficacy supplement, labeling supplement, tentative approval, withdrawal.
Priority-review flag scored above standard reviews.
Impact score 0-100 from event type plus recency; most-recent-first.
A direct Drugs@FDA link and FDA documents (label, letter, review) for every event.

Who uses FDA regulatory data

Biotech and pharma investors and traders building a regulatory-catalyst calendar.
Fintech and research apps embedding approval data.
Competitive-intelligence teams tracking a competitor’s approvals and pipeline actions.

How it works

The tool reads the official openFDA Drugs@FDA API (free, public, JSON), matches the sponsor (with a wildcard fallback so “Vertex” finds “VERTEX PHARMACEUTICALS…”), then classifies and scores each submission. Clean and stable.

Example

Eli Lilly in live data: a new drug approval (original NDA) for FOUNDAYO, scored impact 95. Vertex: a priority-review new-indication supplement for TRIKAFTA, scored impact 80.

Scope and limitation

Covers FDA CDER drug applications in Drugs@FDA. Vaccines and some biologics handled by CBER are not in this dataset. The source provides regulatory actions and approvals, not forward-looking PDUFA target dates (which are not published in a single official feed).

FAQ

What counts as a high-impact event? A new drug approval and priority-review efficacy/new-indication supplements score highest; routine labeling supplements score low. Which companies can I track? Any drug sponsor in Drugs@FDA. Use the company name; a wildcard fallback handles legal-name variations. Is this investment advice? No. It is data for research and monitoring.

Use with AI agents and automation

This runs as an Apify Actor, so it drops into your stack with no scraping or glue code:

AI agents and LLMs: call it as a live tool from LangChain, LlamaIndex or Flowise, or over MCP.
No-code automation: wire it to Zapier or Make (new approval -> calendar, Slack or Google Sheets).
Webhooks and pipelines: fire a webhook on each run, or chain it into another DataSignals Lab product.
API and schedule: JSON output, on demand or on a daily schedule.

Keywords: FDA approval, openFDA, Drugs@FDA, PDUFA, drug approval data, biotech catalyst, priority review, new drug application, NDA, BLA, pharma regulatory data, FDA approval API.